Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effectiveness of a drug called ambrisentan,
approved by the FDA for use in pulmonary hypertension (a condition where there is increased
pressure in the right side of the heart) in scleroderma patients, to see if this medicine may
be beneficial in relieving and/or preventing Raynaud's flares in you and other patients like
you. This medicine may have some short-term and long-term benefits in persons with
scleroderma